0000950170-24-083303.txt : 20240712
0000950170-24-083303.hdr.sgml : 20240712
20240712174604
ACCESSION NUMBER: 0000950170-24-083303
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240710
FILED AS OF DATE: 20240712
DATE AS OF CHANGE: 20240712
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kirn David
CENTRAL INDEX KEY: 0001834021
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39782
FILM NUMBER: 241115370
MAIL ADDRESS:
STREET 1: C/O 4D MOLECULAR THERAPEUTICS INC.
STREET 2: 5858 HORTON STREET #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 4D Molecular Therapeutics, Inc.
CENTRAL INDEX KEY: 0001650648
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 473506994
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5858 HORTON STREET #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5105052680
MAIL ADDRESS:
STREET 1: 5858 HORTON STREET #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc.
DATE OF NAME CHANGE: 20200506
FORMER COMPANY:
FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc
DATE OF NAME CHANGE: 20150811
4
1
ownership.xml
4
X0508
4
2024-07-10
0001650648
4D Molecular Therapeutics, Inc.
FDMT
0001834021
Kirn David
C/O 4D MOLECULAR THERAPEUTICS INC.
5858 HORTON STREET #455
EMERYVILLE
CA
94608
true
true
false
false
Chief Executive Officer
true
Common Stock
2024-07-10
4
M
false
11653
14.42
A
1070806
D
Common Stock
2024-07-10
4
M
false
1270
15.78
A
1072076
D
Common Stock
2024-07-10
4
S
false
12923
22.4869
D
1059153
D
Stock Option (Right To Buy)
14.42
2024-07-10
4
M
false
11653
0
D
2033-12-10
Common Stock
11653
565417
D
Stock Option (Right To Buy)
15.78
2024-07-10
4
M
false
1270
0
D
2032-01-31
Common Stock
1270
148730
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.
The transaction was executed in multiple trades in prices ranging from $22.05 to $23.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company.
By: /s/ Scott Bizily as Attorney-in-fact David Kirn
2024-07-12